June 21, 2022: While we agree that these potential modifications are a great step forward in ensuring that unused medications are properly disposed of, overprescribing continues to be a major problem in the U.S. There should be continued efforts to educate physicians and pharmacists on reducing the number of opioids prescribed and providing alternatives to opioid analgesic prescriptions…
Read More »Tag: opioids
NCHR Comments on the Proposed 2022 Center for Disease Control (CDC) Clinical Practice Guideline for Prescribing Opioids
April 11, 2022: We commend the CDC for their continued efforts to reduce opioid use. However, we are very concerned that the impact of the Box 1 Guideline as currently written will be very harmful to patients.
Read More »NCHR Testimony on Tramadol and Celecoxib for Acute Pain Relief
January 15, 2020. There is absolutely no evidence that this combination drug with an opioid is as effective or more effective than a standard dose of just the NSAID.
Read More »National Center for Health Research Statement on Oxycodegol Before the FDA Advisory Committees
January 14, 2020. This FDA hearing was about the risks and benefits of a new opioid, oxycodegol, for the management of chronic lower back pain. We pointed out that experts now agree that patients with chronic pain should not be started on opioids, which are less effective than other options.
Read More »FDA’s tech overhaul is underway
Politico, January 14, 2020. The FDA is reviewing a handful of pain medications, including some new opioids, as the country continues to struggle with misuse and addiction to narcotics.
Read More »